evidencegaps
Primary study · included by 1 review

Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Bosetti 2013 · Bosetti Cristina, Rosato Valentina, Buniato Danilo, et al. · The oncologist · 2013

Included by

Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
Non-Cochrane · aetiology · 2026 · cited as BOSETTI 2013 · Table 1 (Included MA); References
Outcome this study informsPooled effectEvidenceCertainty
Risk of bladder cancer
Use of thiazolidinediones vs No use
RR 1.13 [1.05, 1.23]7 studies · 2161655 participantsVery low
Risk of bladder cancer
Use of thiazolidinediones: rosiglitazone vs No use
RR 1.08 [0.95, 1.23]3 studies · 1508042 participantsVery low
Risk of bladder cancer
Use of acetaminophen vs No use
RR 1.01 [0.88, 1.17]10 studies · 97108 participantsVery low
Risk of bladder cancer
Duration of pioglitazone use (thiazolidinediones) vs Reference category per source meta-analysis
RR 1.22 [0.93, 1.59]11 studiesVery low
Risk of bladder cancer
Exposure to disinfection by-products vs No exposure
RR 1.59 [1.24, 2.04]11 studies · 978500 participantsVery low

1 including review in total.